---
document_datetime: 2024-10-14 11:12:36
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kapruvia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: kapruvia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.013763
conversion_datetime: 2025-12-15 20:15:58.517259
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Kapruvia

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| IB/0008              | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 25/07/2024                          |                                             | SmPC                             |                                   |
| PSUSA/10995          | Periodic Safety Update EU Single assessment -                                                                                                                                                  | 07/03/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| /202308             | difelikefalin                                                                                                                                                                                                                                |            |            |                                  |                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------|
| IA/0006             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 27/02/2024 | n/a        |                                  |                                                                                                            |
| PSUSA/10995 /202302 | Periodic Safety Update EU Single assessment - difelikefalin                                                                                                                                                                                  | 28/09/2023 | n/a        |                                  | PRAC Recommendation - maintenance                                                                          |
| PSUSA/10995 /202208 | Periodic Safety Update EU Single assessment - difelikefalin                                                                                                                                                                                  | 16/03/2023 | n/a        |                                  | PRAC Recommendation - maintenance                                                                          |
| IB/0002             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                | 21/09/2022 | n/a        |                                  |                                                                                                            |
| IB/0001             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 22/07/2022 | 17/07/2023 | SmPC, Annex II, Labelling and PL | To implement editorial changes in sections 4.8, 5.1 and 5.2 of the SmPC, annex II and section 3 of the PL. |